# Anaheim Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anaheim-bio

- Industry: Health & Biotech
- Headquarters: Leiden, Netherlands
- Website: https://anaheimbio.com/
- Total disclosed funding: $45M
- Latest round: Series A (Nov 5, 2026)
- Investors on record: 6

## About

Leiden-based Anaheim Bio launched with an oversubscribed €40 million Series A to advance ANA-1, a small molecule candidate for calcium pyrophosphate deposition disease, into the clinic. The preclinical biotech was spun out of Alesta Therapeutics and is backed by Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital.

## Funding rounds

- Series A, Nov 5, 2026, $45M — Droia Ventures, Frazier Life Sciences, Novartis Venture Fund, RTW Investments, RV Invest, Thuja Capital

## Investors

- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series A
- Frazier Life Sciences — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series A
- RV Invest (https://capitalatlas.ai/funds/rv-invest) — Series A
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A